Skip to main content

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Validación funcional de variantes en el genoma mitocondrial y nuclear en pacientes con patologia mitocondrial

IP: Elena García Arumí
Collaborators: Mª Jesus Melia Grimal, Clara Carnicer Cáceres, Paula Fernández Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 102850
Reference: PI19/01772
Duration: 01/01/2020 - 31/12/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Belen Perez Dueñas
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Clara Carnicer Cáceres, Mireia del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

INTERACCIONES ENTRE IgA1 DEGALACTOSILADA Y LECTINA DE UNION A MANOSA EN ENFERMOS CON NEFROPATIA IgA: RELACION CON LA ACTIVACION DEL COMPLEMENTO PO

IP: -
Collaborators: Clara Carnicer Cáceres, Irene Agraz Pamplona
Funding agency: Instituto de Salud Carlos III
Funding: 38115
Reference: PI14/01831
Duration: 01/01/2015 - 31/03/2018

Caracterización clínica de variantes patogénicas e investigación de nuevos factores pronósticos en la nefropatía IgA

IP: -
Collaborators: Manuel Hernández González, Clara Carnicer Cáceres, Maria Teresa Salcedo Allende
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI10/01055
Duration: 01/01/2011 - 31/12/2013

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.